Abstract
Introduction

27
Doxorubicin is a highly potent anticancer drug, widely used in chemotherapy for the treatment of various 28 types of cancers such as Kaposi's sarcoma, ovarian carcinoma and breast cancer (Rana et al., 2011) . Despite a high 29 degree of anti-tumour activity, drug resistance and strong adverse effects limit its efficacy. To overcome this 30 problem several delivery strategies have been developed such as solid lipid nanoparticles and nanoliposomal 31 delivery systems, for example Doxil ® (Natarajan et al., 2014) . Ion-exchange microspheres and, in particular, drug-eluting beads, have become the system of choice for drug delivery (Liu et al., 2001; Shuhendler et al., 2010) . For 33 over a decade transarterial chemoembolisation using drug eluting beads (DEBs) has been a treatment option for 34 primary and secondary liver cancers. These drug/device combination microspheres are delivered intra-arterially into 35 tumour-feeding vessels to occlude blood flow, locally delivering a controlled and sustained therapeutic dose and 36 reduced systemic exposure of cytotoxic cancer drugs (Kerr, 1987) . Interactions between the drug and these more 37 recently developed delivery systems is of interest for several reasons, primarily as it is important to fully 38 characterise such formulations to help optimise their bioavailability for the patient. However, the self-association of 
41
One particular device that has shown success in the delivery of doxorubicin (Dox) is the DEB known as the DC
42
Bead™, which is used for the treatment of hypervascular tumours and arteriovenous malformations (Lewis et al., 
52
DC Bead™ to be evaluated in a clinical study was 500-700 µm and was based upon the predicate Gelfoam particles.
53
Gradually the size of DEBs has decreased, as smaller beads are favoured to achieve deeper tumour penetration and 
59
Elution rate and uptake of the drug is dependent upon bead size, as diffusion is inversely proportional to bead size as
60
caused by the increase in surface area to volume ratio. 
67
and modification of the design of a new type of drug delivery system for even more effective targeted drug therapy.
68
To achieve an understanding of the stoichiometry and thermodynamics of the drug-bead interactions requires the application of a technique that can monitor binding phenomena in real-time and at specified temperatures.
70
Isothermal titration calorimetry has the potential to achieve this aim. 
126
Results and Discussion
127
After experimenting with several drug concentrations it was found that 10 mM doxorubicin produced the 128 most suitable ITC profile for injection, although a small demicellisation event was observed which then had to be 
146
Since the mass of Dox had been calculated and the relative molecular mass is known ((C 27 H 29 NO 11 .HCl) 579.99g), Table   155 1 with an overall standard deviation of 0.02. 
156
184
For binding at 293 K the mean enthalpy change was found to be -14.8 kJmol -1 whereas at 313 K was -
185
19.4 kJmol -1
. Although small differences were observed between the temperatures, overall the binding phenomenon 
196
However, the findings from this study were not as straightforward as initially expected when considering 197 the drug to polymer ratio values obtained. Data obtained from previous work on the same drug-bead system (using
198
UV analysis) has demonstrated binding of 37.5 mg per mL of bead, which equates to a Dox:AMPS ratio of 0.7:1
199
(and is unanimously accepted as an achievable value in clinical practice equating to 150 mg in 4 mL of beads, i.e.
200
the standard recommended dose per administration for patients per treatment). Indeed, ratios of 1:1 are also 201 achievable with higher doxorubicin loading concentrations (Fajardo, 2006) , whereas in this study, the ratio was 202 closer to 0.4:1. The difference between these two ratios is most likely a result of differing methods of mixing, the 203 clinical approach routinely involves the complete, rapid addition of drug to bead whereas the ITC method is small,
204
sequential additions. This alternative, latter approach may induce conformational changes within the beads that 205 prevent further drug accessing the binding sites, keeping the ratio lower than that observed using UV analysis.
207
Conclusions
208
In summary, this study has determined the suitability of ITC to investigate drug-excipient interactions such
209
as those between drugs and polymer beads. Moreover, it has been possible to calculate the ratio of drug molecules to
210
SO 3 -groups which appears to be temperature independent and the change in enthalpy with binding is also unaffected 211 by temperature effects. The reasons for differences between the results presented here and UV data are the subject of 212 current research. Finally, it would be of interest to investigate the same bead system with a series of compounds to 213 determine the specificity of the binding process, such as that observed by others for related polymer-drug systems 214 (Govender et al., 2000) . To maximise the efficiency of drug delivery systems, such as those studied in this work, it is 215 essential to fully understand their physicochemical behaviour and then, based on this knowledge, it may be possible 216 to enhance the amount that can be contained within the polymer by maximising drug-polymer interactions. Although 217 the experimental protocol was somewhat dissimilar to that seen in clinical applications, i.e. small aliquots were 218 added over many hours rather than the standard mixing time of 30 minutes prior to injection, it still yields useful 219 information with respect to drug-bead interactions.
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